使用一线凝血因子浓缩物或新鲜冰冻血浆逆转创伤性凝血病(RETIC):单中心、平行组、开放标签、随机试验
在奥地利因斯布鲁克医科大学一级创伤中心进行的单中心、平行组、开放标签随机试验,纳入100例创伤性凝血病患者,随机接受新鲜冰冻血浆(FFP,15 mL/kg体重)或凝血因子浓缩物(CFC,主要为纤维蛋白原浓缩物50 mg/kg体重)治疗。因FFP组需救援治疗比例更高(52% vs 4%)且大量输血需求增加(30% vs 12%),研究提前终止。作者认为一线CFC优于FFP。
要点
- FFP组需救援治疗23例(52%)vs CFC组2例(4%),OR 25.34(95%CI 5.47-240.03),p<0.0001。
- FFP组需大量输血13例(30%)vs CFC组6例(12%),OR 3.04(95%CI 0.95-10.87),p=0.042。
- 多器官衰竭FFP组29例(66%)vs CFC组25例(50%),OR 1.92(95%CI 0.78-4.86),p=0.15。
核心结论
- 作者认为结果强调了对多发伤严重凝血障碍早期有效补充纤维蛋白原的重要性,并认为现有样本量足以得出某些结论,即一线CFC优于FFP。
研究设计与样本
- 单中心、平行组、开放标签、随机试验,在奥地利因斯布鲁克医科大学医院一级创伤中心进行。
- 纳入年龄18-80岁、损伤严重度评分(ISS)大于15、有出血征象、经旋转血栓弹力图(ROTEM)显示纤维蛋白聚合异常或凝血时间延长的创伤性凝血病患者。
- 排除受伤被判定无法存活、现场心肺复苏、孤立性脑损伤、烧伤、雪崩伤或院前接受除氨甲环酸以外凝血治疗的患者。
- 采用计算机生成随机化列表,按脑损伤和ISS分层,使用封闭不透光信封随机分配至FFP(15 mL/kg体重)或CFC(主要为纤维蛋白原浓缩物50 mg/kg体重)治疗。
- 2012年3月3日至2016年2月20日筛查292例患者,纳入100例,随机分配至FFP组(n=48)和CFC组(n=52);6例(FFP组4例,CFC组2例)因遗漏排除标准或重大方案偏离伴失访而终止治疗;最终分析纳入FFP组44例和CFC组50例。
主要发现
- 研究因无效性和安全性提前终止:FFP组需救援治疗23例(52%)vs CFC组2例(4%),OR 25.34(95%CI 5.47-240.03),p<0.0001。
- FFP组需大量输血13例(30%)vs CFC组6例(12%),OR 3.04(95%CI 0.95-10.87),p=0.042。
- 多器官衰竭FFP组29例(66%)vs CFC组25例(50%),OR 1.92(95%CI 0.78-4.86),p=0.15。
局限性
- 研究因无效性和安全性原因提前终止。
- 6例患者(FFP组4例,CFC组2例)因遗漏排除标准或重大方案偏离伴失访而终止治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Effective treatment of trauma-induced coagulopathy is important; however, the optimal therapy is still not known. We aimed to compare the efficacy of first-line therapy using fresh frozen plasma (FFP) or coagulation factor concentrates (CFC) for the reversal of trauma-induced coagulopathy, the arising transfusion requirements, and consequently the development of multiple organ failure. METHODS: This single-centre, parallel-group, open-label, randomised trial was done at the Level 1 Trauma Center in Innsbruck Medical University Hospital (Innsbruck, Austria). Patients with trauma aged 18-80 years, with an Injury Severity Score (ISS) greater than 15, bleeding signs, and plasmatic coagulopathy identified by abnormal fibrin polymerisation or prolonged coagulation time using rotational thromboelastometry (ROTEM) were eligible. Patients with injuries that were judged incompatible with survival, cardiopulmonary resuscitation on the scene, isolated brain injury, burn injury, avalanche injury, or prehospital coagulation therapy other than tranexamic acid were excluded. We used a computer-generated randomisation list, stratification for brain injury and ISS, and closed opaque envelopes to randomly allocate patients to treatment with FFP (15 mL/kg of bodyweight) or CFC (primarily fibrinogen concentrate [50 mg/kg of bodyweight]). Bleeding management began immediately after randomisation and continued until 24 h after admission to the intensive care unit. The primary clinical endpoint was multiple organ failure in the modified intention-to-treat population (excluding patients who discontinued treatment). Reversal of coagulopathy and need for massive transfusions were important secondary efficacy endpoints that were the reason for deciding the continuation or termination of the trial. This trial is registered with ClinicalTrials.gov, number NCT01545635. FINDINGS: Between March 3, 2012, and Feb 20, 2016, 100 out of 292 screened patients were included and randomly allocated to FFP (n=48) and CFC (n=52). Six patients (four in the FFP group and two in the CFC group) discontinued treatment because of overlooked exclusion criteria or a major protocol deviation with loss of follow-up. 44 patients in the FFP group and 50 patients in the CFC group were included in the final interim analysis. The study was terminated early for futility and safety reasons because of the high proportion of patients in the FFP group who required rescue therapy compared with those in the CFC group (23 [52%] in the FFP group vs two [4%] in the CFC group; odds ratio [OR] 25·34 [95% CI 5·47-240·03], p<0·0001) and increased needed for massive transfusion (13 [30%] in the FFP group vs six [12%] in the CFC group; OR 3·04 [0·95-10·87], p=0·042) in the FFP group. Multiple organ failure occurred in 29 (66%) patients in the FFP group and in 25 (50%) patients in the CFC group (OR 1·92 [95% CI 0·78-4·86], p=0·15). INTERPRETATION: Our results underline the importance of early and effective fibrinogen supplementation for severe clotting failure in multiple trauma. The available sample size in our study appears sufficient to make some conclusions that first-line CFC is superior to FFP. FUNDING: None.
引用
- Innerhofer P, Fries D, Mittermayr M, et al. Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial. Lancet Haematol. 2017. PMID: 28457980. doi:10.1016/S2352-3026(17)30077-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。